<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585390</url>
  </required_header>
  <id_info>
    <org_study_id>Richtand #1</org_study_id>
    <nct_id>NCT00585390</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out what effects (good and bad) that omega-3&#xD;
      fatty acids has on schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two aims of the study test the hypotheses that correcting omega-3 fatty acid deficiency&#xD;
      in the early stages of schizophrenia improves positive symptom treatment response, negative&#xD;
      symptom treatment response, and cognition symptom response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine positive symptom treatment response in omega-3 fatty acid deficient first-episode schizophrenia patients augmented with omega-3 fatty acid supplementation vs. placebo.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine negative and cognitive symptom treatment response in omega-3 fatty acid deficient first-episode schizophrenia patients augmented with omega-3 supplementation vs. placebo.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Fatty Acid Deficiency</condition>
  <arm_group>
    <arm_group_label>Essential omega-3 fatty acid replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Fatty Acids</intervention_name>
    <description>Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams&#xD;
Docosahexaenoic acid fish oil concentrate at 1.6 grams</description>
    <arm_group_label>Essential omega-3 fatty acid replacement</arm_group_label>
    <other_name>EPA</other_name>
    <other_name>DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olive oil placebo</intervention_name>
    <description>Olive oil capsules, 8 capsules per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Olive oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA fish oil concentrate; DHA fish oil concentrate</intervention_name>
    <description>3.2 grams for EPA 1.6 grams for DHA</description>
    <arm_group_label>Essential omega-3 fatty acid replacement</arm_group_label>
    <other_name>Eicosapentaenoic acid (EPA)</other_name>
    <other_name>Docosahexaenoic acid (DHA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olive oil capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Olive oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 8-25 years.&#xD;
&#xD;
          -  Diagnosis of MDD and not exhibited symptom remission CDRS-R (&gt; 28 but &lt; 40) despite&#xD;
             being administered a standard therapeutic dose of an SSRI continuously for a minimum&#xD;
             of 6 weeks.&#xD;
&#xD;
          -  Ability and willingness to provide assent and informed, written consent from at least&#xD;
             one biological parent.&#xD;
&#xD;
          -  Present with biological parent or legal guardian.&#xD;
&#xD;
          -  Willingness to maintain current dietary habits.&#xD;
&#xD;
          -  Permission from treating physician&#xD;
&#xD;
          -  Able to perform fMRI/MRS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness to provide consent.&#xD;
&#xD;
          -  Antecedent or concurrent serious medical illness.&#xD;
&#xD;
          -  Clinically unstable medical disease, including cardiovascular, hepatic insufficiency,&#xD;
             severe renal impairment, gastrointestinal, pulmonary, metabolic, endocrine, obesity or&#xD;
             other systemic disease.&#xD;
&#xD;
          -  History of seizures, excluding febrile seizures in childhood.&#xD;
&#xD;
          -  Patients requiring treatment with any drug which might obscure the action of the study&#xD;
             treatment.&#xD;
&#xD;
          -  Female patients who are either pregnant or lactating.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities in the last year on CBC or TSH tests.&#xD;
&#xD;
          -  Judged clinically to be at suicidal risk (defined as having active suicidal ideation,&#xD;
             intent or plan, or a serious suicide attempt within the past 6 months, or a baseline&#xD;
             CDRS-R suicide score of &gt;3).&#xD;
&#xD;
          -  Hospitalized within the last 3 months&#xD;
&#xD;
          -  Greater than 1 year outside appropriate age/grade level&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Cerebral aneurysm clip&#xD;
&#xD;
          -  Cochlear implant&#xD;
&#xD;
          -  Metal fragments lodged within the eye or braces&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Necessity of sedation (no sedation will be given).&#xD;
&#xD;
          -  History of loss of consciousness &gt; 10 minutes in duration&#xD;
&#xD;
          -  Allergy to seafood.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Richtand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Neil Richtand, MD / Professor</name_title>
    <organization>University of Cincinnati</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

